{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:26:09Z","timestamp":1787167569385,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian Dermatol Online J"],"published-print":{"date-parts":[[2020]]},"DOI":"10.4103\/idoj.idoj_520_19","type":"journal-article","created":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T04:44:12Z","timestamp":1638765852000},"page":"738","source":"Crossref","is-referenced-by-count":9,"title":["Clinical profile of overgrowth syndromes consistent with PROS (PIK3CA-related overgrowth syndromes)\u2014A case series"],"prefix":"10.4103","volume":"11","author":[{"given":"Renu","family":"George","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sniya","family":"Sudhakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ShyamkumarN","family":"Keshava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NA","family":"Fouzia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2229-5178.295582-1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/ajmg.a.36836","article-title":"PIK3CA-related overgrowth spectrum (PROS): Diagnostic and testing eligibility criteria, differential diagnosis, and evaluation","author":"Keppler-Noreuil","year":"2015","journal-title":"Am J Med Genet A"},{"key":"key-10.4103\/2229-5178.295582-2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/gim.2016.220","article-title":"Molecular diagnosis of PIK3CA-related overgrowth spectrum (PROS) in 162 patients and recommendations for genetic testing","author":"Kuentz","year":"2017","journal-title":"Genet Med"},{"key":"key-10.4103\/2229-5178.295582-3","doi-asserted-by":"crossref","first-page":"12e","DOI":"10.1097\/01.prs.0000436822.26709.7c","article-title":"PIK3CA activating mutations in facial infiltrating lipomatosis","author":"Maclellan","year":"2014","journal-title":"Plast Reconstr Surg"},{"key":"key-10.4103\/2229-5178.295582-4","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/ajmg.a.38105","article-title":"Somatic PIK3CA mutations in seven patients with PIK3CA-related overgrowth spectrum","author":"Yeung","year":"2017","journal-title":"Am J Med Genet A"},{"key":"key-10.4103\/2229-5178.295582-5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/cge.12819","article-title":"Utility of clinical high-depth next generation sequencing for somatic variant detection in the PIK3CA-related overgrowth spectrum","author":"Hucthagowder","year":"2017","journal-title":"Clin Genet"},{"key":"key-10.4103\/2229-5178.295582-6","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/bjd.14618","article-title":"Phenotypic heterogeneity in PIK3CA-related overgrowth spectrum","author":"Vahidnezhad","year":"2016","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/2229-5178.295582-7","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.molmed.2018.08.003","article-title":"Cancer-associated PIK3CA mutations in overgrowth disorders","author":"Madsen","year":"2018","journal-title":"Trends Mol Med"},{"key":"key-10.4103\/2229-5178.295582-8","doi-asserted-by":"crossref","first-page":"e0123092","DOI":"10.1371\/journal.pone.0123092","article-title":"Molecular and functional characterization of three different postzygotic mutations in PIK3CA-related overgrowth spectrum (PROS) patients: Effects on PI3K\/AKT\/mTOR signaling and sensitivity to PIK3 inhibitors","author":"Loconte","year":"2015","journal-title":"PLoS One"},{"key":"key-10.4103\/2229-5178.295582-9","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1002\/ajmg.a.36552","article-title":"Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum","author":"Keppler-Noreuil","year":"2014","journal-title":"Am J Med Genet A"},{"key":"key-10.4103\/2229-5178.295582-10","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/ajmg.a.36454","article-title":"Segmental overgrowth syndrome due to an activating PIK3CA mutation identified in affected muscle tissue by exome sequencing","author":"Rasmussen","year":"2014","journal-title":"Am J Med Genet A"},{"key":"key-10.4103\/2229-5178.295582-11","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/hmg\/dds440","article-title":"Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly","author":"Rios","year":"2013","journal-title":"Hum Mol Genet"},{"key":"key-10.4103\/2229-5178.295582-12","first-page":"e87623","article-title":"PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution","author":"Mirzaa","year":"2016","journal-title":"JCI Insight"},{"key":"key-10.4103\/2229-5178.295582-13","first-page":"71","article-title":"A rare newly described overgrowth syndrome with vascular malformations-cloves syndrome","author":"Gopal","year":"2015","journal-title":"Indian J Radiol Imaging","ISSN":"https:\/\/id.crossref.org\/issn\/0971-3026","issn-type":"print"},{"key":"key-10.4103\/2229-5178.295582-14","first-page":"e5772","article-title":"CLOVES syndrome in a nine-month-old infant","author":"Alomar","year":"2019","journal-title":"Cureus"},{"key":"key-10.4103\/2229-5178.295582-15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ijporl.2019.06.032","article-title":"Congenital infiltrating lipomatosis of the face: A subtype of hemifacial hyperplasia","author":"Sun","year":"2019","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"key-10.4103\/2229-5178.295582-16","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1002\/ajmg.a.32023","article-title":"Newly delineated syndrome of congenital lipomatous overgrowth, vascular malformations, and epidermal nevi (CLOVE syndrome) in seven patients","author":"Sapp","year":"2007","journal-title":"Am J Med Genet A"},{"key":"key-10.4103\/2229-5178.295582-17","unstructured":"Mirzaa G, Conway R, Graham JM, Dobyns WB. PIK3CA-related segmental overgrowth. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, et al. editors. GeneReviews\u00ae. Seattle (WA): University of Washington, Seattle; 1993."},{"key":"key-10.4103\/2229-5178.295582-18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/cge.12832","article-title":"CLOVES syndrome: Review of a PIK3CA-related overgrowth spectrum (PROS)","author":"Martinez-Lopez","year":"2017","journal-title":"Clin Genet"},{"key":"key-10.4103\/2229-5178.295582-19","first-page":"30","article-title":"PI3K signaling in tissue hyper-proliferation: From overgrowth syndromes to kidney cysts","author":"De","year":"2017","journal-title":"Cancers"},{"key":"key-10.4103\/2229-5178.295582-20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MCD.0b013e328317a716","article-title":"Characterization of a distinct syndrome that associates complex truncal overgrowth, vascular, and acral anomalies: A descriptive study of 18 cases of CLOVES syndrome","author":"Alomari","year":"2009","journal-title":"Clin Dysmorphol"},{"key":"key-10.4103\/2229-5178.295582-21","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrd2926","article-title":"Targeting the phosphoinositide 3-kinase pathway in cancer","author":"Liu","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"key-10.4103\/2229-5178.295582-22","first-page":"299","article-title":"Targeting the PI3K\/AKT\/mTOR signaling axis in children with hematologic malignancies","author":"Barrett","year":"2012","journal-title":"Paediatr Drugs"},{"key":"key-10.4103\/2229-5178.295582-23","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/sj.ejhg.5201026","article-title":"Overgrowth syndromes: Is dysfunctional PI3-kinase signalling a unifying mechanism?","author":"Barker","year":"2003","journal-title":"Eur J Hum Genet"},{"key":"key-10.4103\/2229-5178.295582-24","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/ng.2331","article-title":"De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes","author":"Rivi\u00e8re","year":"2012","journal-title":"Nat Genet"},{"key":"key-10.4103\/2229-5178.295582-25","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/ng.2329","article-title":"De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly","author":"Lee","year":"2012","journal-title":"Nat Genet"},{"key":"key-10.4103\/2229-5178.295582-26","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41586-018-0217-9","article-title":"Targeted therapy in patients with PIK3CA-related overgrowth syndrome","author":"Venot","year":"2018","journal-title":"Nature"}],"container-title":["Indian Dermatology Online Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:24:11Z","timestamp":1787163851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.IDOJ_520_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020]]}},"alternative-id":["295582"],"URL":"https:\/\/doi.org\/10.4103\/idoj.idoj_520_19","relation":{},"ISSN":["2229-5178"],"issn-type":[{"value":"2229-5178","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}